Vice Chancellor Myron Steele approved a lawsuit settlement that will provide about $44 million to investors who claim they were underpaid when marketing rights to a drug developed for heart patients were sold to Eli Lilly and Co.

A unit of PaineWebber Inc. bought limited partnership units in a Centocor Inc. subsidiary that was developing the heart drug ReoPro. In 1992, Centocor sold the exclusive marketing rights to ReoPro and other items to Eli Lilly for $100 million. However, only $500,000 of the transaction was attributed to the purchase of ReoPro’s marketing rights.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]